Table 2.
Clinical goals for target structures and OARs alongside average results from all five cases for the non-robust and robust plans in the nominal (planning CT) geometry. For the PTVs, the D95% and D98% were mandatory and optimal, respectively. All OAR constraints were mandatory. All plans were normalised such that the Breast PTV achieved a D50% of prescription dose meaning a statistical test for this metric is not recorded.
| ROI | Statistic | Clinical goal | Nominal (planning CT) scenario for all five cases |
p-values | |||
|---|---|---|---|---|---|---|---|
| robust |
Non-robust |
||||||
| median | IQ range | median | IQ range | ||||
| Breast PTV | D98 (Gy) | >38.05 | 37.9 | 37.7–38.0 | 38.1 | 37.8–38.2 | 0.13 |
| D95 (Gy) | >38.05 | 38.6 | 38.5–38.6 | 38.7 | 38.4–38.8 | 0.47 | |
| D50 (Gy) | 40.05 ± 0.80 | 40.1 | 40.1–40.1 | 40.1 | 40.1–40.1 | n/a | |
| D2 (Gy) | <42.85 | 41.6 | 41.3–41.6 | 41.2 | 41.2–41.2 | 0.04 | |
| Axillary PTV | D98 (Gy) | >38.05 | 38.4 | 38.4–38.5 | 38.6 | 38.5–38.8 | 0.04 |
| D95 (Gy) | >38.05 | 38.7 | 38.7–38.9 | 38.9 | 38.8–39.1 | 0.04 | |
| D50 (Gy) | 40.05 ± 0.80 | 39.6 | 39.6–39.7 | 39.8 | 39.8–39.8 | 0.08 | |
| D2 (Gy) | <42.85 | 40.6 | 40.4–40.7 | 40.8 | 40.7–40.8 | 0.22 | |
| IMC PTV | D98 (Gy) | >38.05 | 37.6 | 37.2–38.0 | 38.5 | 37.9–38.8 | 0.04 |
| D95 (Gy) | >38.05 | 38.3 | 38.1–38.6 | 38.9 | 38.7–39.1 | 0.04 | |
| D50 (Gy) | 40.05 ± 0.80 | 39.8 | 39.8–40.0 | 40.1 | 40.0–40.2 | 0.04 | |
| D2 (Gy) | <42.85 | 40.8 | 40.8–40.9 | 41.0 | 41.0–41.0 | 0.04 | |
| Heart | mean (Gy) | <6.00 | 3.8 | 3.6–5.5 | 3.9 | 3.7–5.5 | 0.68 |
| Left Lung | V17Gy (%) | <35 | 33.1 | 32.4–34.2 | 33.4 | 32.5–33.8 | 0.71 |
| mean (Gy) | <15 | 13.6 | 13.6–13.8 | 13.6 | 13.5–13.9 | 0.72 | |
| Right Lung | mean (Gy) | <3.5 | 3.3 | 3.2–3.3 | 3.3 | 3.2–3.3 | 0.32 |
| Right Breast | mean (Gy) | <3.5 | 3.3 | 3.3–3.3 | 3.3 | 3.3–3.4 | 0.65 |
IQ = inter-quartile. PTV = Planning Target Volume.